# CURAMYS

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/curamys

- Industry: Healthcare
- Headquarters: Seoul, South Korea
- Website: www.curamys.com
- Total disclosed funding: $8.5M
- Latest round: Series A (Oct 19, 2021)
- Investors on record: 3

## About

Curamys is a biotechnology company focused on developing cell and gene therapies aimed at treating rare and intractable diseases, utilizing proprietary cell fusion technology to innovate therapeutic solutions.Curamys Co., Ltd. was founded in 2018 in Seoul, South Korea, specializing in cell and gene therapies. The company has successfully completed 3 deals, with its most recent being a Series A funding round on October 19, 2021, where it raised KRW 10 billion led by ID Ventures, with participation from DSC Investment and HB Investment. Mr. Jeong-joon Seong continues to serve as the CEO of Curamys.Curamys Co., Ltd. specializes in developing cell and gene therapies for rare and intractable diseases by leveraging proprietary cell fusion technology. Their core offerings encompass innovative therapeutic solutions designed to fundamentally treat rare genetic disorders and provide diagnostics. They cater to a diverse clientele, including healthcare institutions and research organizations, with a strong focus on North America and Europe, addressing unmet medical needs in the gene therapy sector.Curamys generates revenue primarily through B2B transactions, collaborating with healthcare providers and research institutions to offer specialized cell and gene therapies. These partnerships often involve long-term arrangements that integrate their products into clinical settings and may include direct sales of therapies and diagnostic solutions, tailored pricing plans aimed at delivering value through their key therapeutic offerings.In October 2021, Curamys raised KRW 10 billion in Series A funding led by ID Ventures, with new investments from DSC Investment and HB Investment. This investment will expedite the clinical development of a new drug for fusion-competent stem cells, aiming for approval of clinical trials in Korea in 2023. The company plans to introduce new products targeting rare diseases and aims to expand its market reach in North America and Europe.

## Funding rounds

- Series A, Oct 19, 2021, $8.5M — HB Investment, DSC Investment, ID Ventures

## Investors

- HB Investment (https://capitalatlas.ai/funds/hb-investment) — Series A
- DSC Investment (https://capitalatlas.ai/funds/dsc-investment) — Series A
- ID Ventures (https://capitalatlas.ai/funds/id-ventures) — Series A